Compounds of the formulas ##SPC1## In which R.sub.1 stands for branched alkyl, alkenyl or cycloalkyl having at least three carbon atoms or hydroxyalkyl. R' stands for free or substituted amino, hydrazino, halogen or free or etherified mercapto, and R" stands for hydrogen, alkyl or for R' for example: the 2-ispropyl-4-mercapto-pyrazolo[3,4-d]pyrimidine. Use: Coronary dilatating, diuretic, analgetic or antibacterial agents.
CROSS-REFERENCES TO OTHER APPLICATIONS
This is a divisional application of our copending application Ser. No. 649,118, filed June 27, 1967, now U.S. Pat. No. 3,551,428, which is in turn a divisional application of our application Ser. No. 292,783, filed July 3, 1963, now U.S. Pat. No. 3,399,196 which is a continuation-in-part application of our application, Ser. No. 815,826, filed May 26, 1959, now abandoned, which itself is a continuation-in-part application of our application Ser. No. 775,334, filed Nov. 21, 1958, now abandoned, which itself is a continuation-in-part application of our application Ser. No. 667,042, filed June 20, 1957, now U.S. Pat. No. 2,980,677; application Ser. No. 292,783 is also a continuation-in-part application of our application, Ser. No. 815,824, filed May 26, 1959, now U.S. Pat. No. 3,187,006, which itself is a continuation-in-part application of our application, Ser. No. 775,356, filed Nov. 21, 1958, now abandoned, which itself is a continuation-in-part application of our application, Ser. No. 637,895, filed Feb. 4, 1957, now abandoned.
Heterocyclic compounds of the formula: ##STR1## WHEREIN ONE OF Y and Z is CH, the other being N, A is a straight or branched saturated hydrocarbon chain from C.sub.2 to C.sub.6 inclusive, X is chlorine, hydroxy, alkoxy or alkylthio each from C.sub.1 to C.sub.5 inclusive, R is hydrogen, alkyl, hydroxyalkyl or dihydroxyalkyl each from C.sub.1 to C.sub.3 inclusive, R' is halogen, alkyl or alkoxy each from C.sub.1 to C.sub.3 inclusive and n is 0, 1 or 2. These compounds, their optical isomers and their physiologically tolerable salts are used as medicines especially in the treatment of central nervous system disorders.
The present invention provides pyrazolo[3,4-d]-pyrimidines of the general formula: ##STR1## wherein R.sub.1 is a C.sub.1 to C.sub.6 -alkyl radical, a C.sub.2 to C.sub.6 -alkenyl radical, a C.sub.3 to C.sub.7 -cycloalkyl radical or an aryl radical, R.sub.2 is a C.sub.2 to C.sub.6 -alkenyl radical, a C.sub.3 to C.sub.7 -cycloalkyl radical or an aralkyl or hetaralkyl radical with 1 to 6 carbon atoms in the alkyl moiety and substituted, if desired, one or more times by halogen, C.sub.1 to C.sub.6 -alkyl, hydroxyl, C.sub.1 to C.sub.6 -alkoxy, C.sub.1 to C.sub.3 -haloalkyl, C.sub.3 to C.sub.7 -alkoxy carbonyl, aminocarbonyl, C.sub.2 to C.sub.7 -alkylaminocarbonyl, C.sub.3 to C.sub.13 -dialkylaminocarbonyl, cyano or C.sub.1 to C.sub.6 -alkylthio and R.sub.3 is a hydrogen atom or a C.sub.2 to C.sub.6 -alkyl radical substituted, if desired, one or more times by hydroxyl or is a tetrahydrofuranyl or tetrahydropyranyl radical, with the proviso that R.sub.2 cannot be an unsubstituted benzyl radical when R.sub.1 is a methyl radical, and the physiologically acceptable salts thereof with inorganic and organic acids. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them.
Pyrrolo[3,4-d]pyrimidines of the following formula: ##STR1## wherein: R is hydrogen, (C.sub.1-4)alkyl, benzyl or chloro-substituted benzyl; R.sub.1 is hydrogen, (C.sub.1-4)alkyl, phenyl or phenyl substituted with methyl, ethyl, methoxy, hydroxy, chloro, fluoro or bromo; R.sub.2 is hydrogen, (C.sub.1-4)alkyl, phenyl or amino; R.sub.3 is hydrogen or (C.sub.1-4)alkyl; D is a divalent radical selected from the groups ##STR2## wherein the carbon atoms are linked to the carbon atom of the pyrrole nucleus and R.sub.4 represents hydroxy, (C.sub.1-4)alkyl or phenyl; and a salt thereof with a pharmaceutically-acceptable acid. The compounds are useful as antiinflammatories and as prostaglandin synthetase inhibitors.
The present invention provides new heterocyclic substituted cyclopentane compounds that are useful in inhibiting adenosine kinase. The present invention also provides pharmaceutical compositions containing such compounds and methods of using such compounds for inhibiting adenosine kinase.
Compounds of the class of substituted or unsubstituted 4-amino-3-(5-nitro-2-furyl)-1H-pyrazolo[3,4-d]pyrimidine and their 5-N oxides have antimicrobial properties and are active ingredients in pharmaceutical compositions and animal feedstuff compositions, an illustrative example is 4-amino-1-methyl-3-(5-nitro-2-furyl)-1H-pyrazolo[3,4-d]pyrimidine.
